Last reviewed · How we verify
Selenomethionine (SLM) (selenomethionine-slm)
At a glance
| Generic name | selenomethionine-slm |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab (PHASE1, PHASE2)
- SLM + Axitinib for Clear Cell RCC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Selenomethionine (SLM) CI brief — competitive landscape report
- Selenomethionine (SLM) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI